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HANDGRIP STRENGTH IN CANCER SURVIVORS: 2011-2014 NATIONAL HEALTH
AND NUTRITION EXAMINATION SURVEY

AYLA M. KIBLER
29 Pages
Cachexia, or a loss of muscle mass, has been identified as a potential indicator of cancer
survival rates. Previous explorations in research have connected muscular strength to muscle loss
and cancer survivorship, but nationally generalizable findings are limited. PURPOSE: To
investigate handgrip strength in cancer survivors using the National Health and Nutrition
Examination Survey (NHANES), a nationally representative sample of US adults. METHODS:
The analysis included 368 males and 425 females from the 2011-2014 NHANES dataset. Cancer
survivor information (type of cancer and age of diagnosis) was determined by questionnaire.
Cancer types were grouped into the following: skin cancers, reproductive cancers, other cancers
(digestive, nervous, respiratory, musculoskeletal, renal, and endocrine), and multiple or other
cancers. Muscular strength was assessed using a handgrip dynamometer and expressed as
relative grip strength z-scores. Low grip strength was categorized as < 33rd percentile and
sufficient strength was defined as relative grip strength at or above the 33rd percentile. Logistic
regression was used to estimate the odds of low relative grip-strength by cancer group and years
from diagnosis, along with the following covariates: age, sex, minority status, social economic
status (SES), body mass index (BMI), and physical activity (PA). A general linear model was
also used to compare the effects of the previously mentioned cancer variables and covariates on
continuous relative grip-strength z-scores. All analyses accounted for NHANES complex
sampling, strata, weight, and clustering of data. RESULTS: In relation to relative grip strength,

the cancer groups nor the years since diagnosis had a statistically significant impact on relative
strength. Low relative grip strength was found only to be correlated with BMI (p<0.001) and PA
(p=0.021). CONCLUSION: Cancer type and time since diagnosed with cancer were not found to
be predictive of low relative grip strength. Other covariates, such as BMI and PA, were better
predictors of low strength in cancer survivors. These results bring forth the importance of
longitudinal analyses that look at strength before, during, and after a cancer diagnosis, in
addition to details about the cancer diagnosis and treatments.
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CHAPTER I: INTRODUCTION
In 2020, the National Cancer Institute estimated that by the end of the year there would
be 1,806,590 new cases of cancer diagnosed in the United States and 606,520 people would die
from the disease1. Many cancer patients, also known as cancer survivors, frequently experience
an involuntary loss of weight, in particular loss of muscle mass, defined as cachexia2. In cancer
survivors, any individual who has been diagnosed with cancer, cachexia is extremely prevalent,
significantly reduces survival rates, and is the primary cause of death in one-quarter of the
patients with advanced solid tumors3. Scientific understanding of cachexia has greatly improved
in recent years, yet cancer cachexia still remains an unmet medical need and attempts towards a
standard treatment guideline have been unsuccessful 4.
Muscle strengthening may assist with the loss of muscle mass from cancer cachexia and
may also being a predictor of cancer outcomes. One treatment used in an attempt to reverse the
muscle/strength loss is exercise. Physical activity has proven to have a positive impact on cancer
treatment related adverse effects5; patients who exercised, compared to patients who did not,
experienced less negative effects and had a lower relative risk of cancer mortality and
recurrence. In 2018, researchers6 used the National Health and Nutrition Examination Survey to
assess 2773 individuals aged 50 or older. After adjusting for covariates, individuals in the upper
quartile for muscle strength were at a 50% reduced risk of cancer specific mortality. There is also
strong evidence for an association between reduced risk of bladder, breast, colon, endometrial,
esophageal, renal, and gastric cancers and physical activity7. The same study also found a
relationship between decreased all cause and cancer mortality and greater activity in individuals
diagnosed with breast, colorectal, or prostate cancer, with up to 50% risk reduction.

1

Unfortunately, few studies have described muscle strength across a diverse group of
cancer survivors. This data would be helpful since different diagnoses and treatments of cancer
have different effects on the survivors. In addition, cancer and muscle strength varies across
different demographics, for example, age and sex. The literature has indicated links between
strength and its impact on cancer survivorship, however, with studies being limited to small
sample sizes and specific cancer types, there is a lack of nationally generalizable findings.
Therefore, the purpose of this descriptive study is to explore handgrip strength in a large group
of cancer survivors using the National Health and Nutrition Examination Survey (NHANES), a
nationally representative sample.
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CHAPTER II: METHODS
Sample
Participants were from NHANES (2011-2014), a program used to assess the health and
nutrition status of adults and children in the United States. This survey examines approximately
5,000 people each year via complex, multistage sampling. After processing inclusion criteria
(full existing data of cancer diagnosis, grip strength, and other covariates), the final analytical
sample included 793 subjects (unweighted), 368 males and 425 females. The National Center for
Health Statistics (NCHS) reviewed and approved NHANES protocols. Informed consent was
obtained from all participants.
Anthropometric Measures
Standing height was measured to the nearest 0.1 cm using a stadiometer (Seca, Hamburg,
Germany) with a vertical backboard and headpiece. Body mass was measured to the nearest 0.1
kg on a digital weight scale (Mettler Toledo, Columbus, OH). Body mass index (BMI) was
calculated as mass in kilograms divided by height in meters squared (kg/m2); subjects’ BMI was
categorized by underweight (>18.5), normal weight (18.5-24.9), overweight (25-29.9), or obese
(≥30).
Grip Strength
Muscular strength was measured via isometric grip strength using a handgrip
dynamometer (Takei, Model T.K.K.5401, Niigata, Japan). A common way to assess muscular
strength in this population is the handgrip test due to it being a feasible and valid predictor of
total body muscular strength8. The hand dynamometer was adjusted to fit the participant’s hand
size. A practice trial was given to make sure the participant understood the procedure and that
the grip size fit properly. Participants were tested standing with their elbow fully extended at the
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side without allowing the dynamometer to touch the body. Participants were asked to squeeze the
dynamometer has hard as possible, making sure to exhale while squeezing. Each hand was tested
three times, alternating between right and left, with a 60 second rest between measurements. The
highest readings from each the left and right hand were taken and summed together for combined
grip strength. Relative grip strength was then calculated by taking the participant’s combined
grip strength and dividing it by body mass (kg strength/ kg mass). An LMS growth model was
used to calculate Z-scores from ages 20-80 years old; these relative Z-scores allow for
standardization of grip strength by sex and age.
Cancer
Cancer was assessed in NHANES using a questionnaire which asks, “Ever told (by a
doctor) you have cancer or malignancy?” to which subjects may reply, “Yes”, “No, “Don’t
Know”. Then, participants were asked to list the types of cancer they have been diagnosed with,
up to three types. The categories include bladder, blood, bone, brain, breast, cervix, colon,
esophagus, gallbladder, kidney, larynx, leukemia, liver, lung, lymphoma, melanoma,
mouth/tongue/lip, nervous system, ovary, pancreas, prostate, rectum, skin (non-melanoma), skin
(unknown), soft tissue, stomach, testis, thyroid, uterus, other, or more than 3 kinds. This list was
narrowed down and grouped into common subcategories: skin, reproductive, other cancers, or
those reported as “multiple” or “other”. NHANES also recorded the age when the cancer was
first diagnosed. From this, an age difference variable was created by subtracting current age from
the age of diagnosis. This allowed us to see how recently the diagnosis occurred.
Covariates
All analyses controlled for age, sex, race/ethnicity, physical activity, and socioeconomic
status. The categories for race/ethnicity were Mexican American, other Hispanic, non-Hispanic
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white, non-Hispanic black, and other race/multiracial. Race from this population was primarily
non-Hispanic white; therefore, two groups were made: non-Hispanic white and minority groups.
Physical activity was based on a questionnaire given to the subjects asking how many minutes of
activity they achieve per week at a moderate vigorous intensity. The participants reported
minutes of vigorous-intensity work, minutes of moderate-intensity work, minutes walking or
bicycling for transportation, minutes of vigorous recreation activities, and minutes of moderate
recreation activities. These answers were summed into total minutes of moderate to vigorous
physical activity per week. Socioeconomic status was measured by calculating the subjects’
family income to poverty level ratio (FIPR). This was accomplished by dividing family income
by the poverty guidelines, specific to family size, appropriate for the geographic location in the
year of data collection.
Statistical Analysis
Descriptive statistics were calculated for individuals previously diagnosed with cancer,
and each covariate separated by sex. A logistic regression was used to determine the odds of low
relative grip-strength Z-scores (low strength < 33rd percentile vs. sufficient strength ≥ 33rd
percentile) with the following covariates: sex, minority status, social economic status, BMI
group, and physical activity. This logistic regression also sought to examine the differences
between the cancer type subcategories. A general linear model was also used to compare the
effects of the previously mentioned covariates on relative grip-strength Z-scores, with the
additional covariate of years since the subjects’ diagnosis. All of the above analyses accounted
for NHANES’ complex sampling, including the strata, the weight, and the clustering of the data.
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CHAPTER III: RESULTS
Descriptive statistics for male and female cancer survivors are displayed in Table 1. The
total sample was comprised of 87% individuals who categorized themselves as non-Hispanic
white with an average FIPR score of 3.3 (SD). The average age was 62 (SD) years and the
average number of years since their most recent cancer diagnosis was 10 (SD) years. The
prevalence of various cancer types in males and females are presented in Table 2. For males, the
top two cancer types were integumentary/skin cancer at 47.9% (3.1) and reproductive at 18.6%
(2.4). For females, the top two cancer types were reproductive 40.3% (3.1) and
integumentary/skin at 28.8% (2.9).
A general linear model (ANOVA) was also used to compare the effects of types of cancer
groups and number of years since the subjects’ cancer diagnosis, along with sex, minority status,
social economic status, body mass index, and physical activity on relative grip-strength Z-scores.
As displayed in Table 3, body mass index and physical activity were statistically significant
predictors of low relative grip strength. According to the results, individuals who are overweight
are 7.66 times more likely to have low relative grip strength, and individuals who are obese are
48.04 times more likely (p<0.001). Participants who recorded 0 minutes of physical activity were
2.17 times more likely to have low relative grip strength compared to individuals who meet the
recommended physical activity of 150 min/week, and those who engage in 1-149 minutes of
physical activity were 1.64 times more likely to have low relative grip strength (p=0.021).
Individuals diagnosed with reproductive cancer were 1.97 times more likely than those with skin
cancer to have low strength scores; digestive, nervous, respiratory, musculoskeletal, renal, and
endocrine cancer diagnoses were 1.23 times more likely than those with skin cancer; those with
multiple cancers or recorded “other” were 2.05 times more likely than skin cancers to have low
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hand grip strength (p=0.074). Individuals who were diagnosed within 3 years or less were 1.75
times more likely to have low strength scores compared to those who were diagnosed 4 or more
years ago (p=0.068). However, both the cancer groups and diagnosis within 3 years were not
found to be statistically significant.
A logistic regression was used to determine the odds of low relative grip-strength Zscores (low strength < 33rd percentile vs. sufficient strength ≥ 33rd percentile) with the previously
mentioned covariates. This logistic regression also sought to examine the differences between
the cancer subcategories and the years from cancer diagnosis. Relative grip strength scores
categorized by years since the subject’s first cancer diagnosis can be found in Table 4. For
individuals in the lower 33rd percentile for strength scores, 21.7% was made up of patient’s
whose diagnoses were within 0 to 1 year, those within 2 to 5 years constituted 24.2%, and last,
those 6 or more years away from their first cancer diagnosis made up the remaining 54.1%.
Sufficient strength included 17.2% individuals 0 to 1 year from their diagnosis, 2 to 5 years also
was 19.9%, and finally 6 or more years since diagnosis made up 57.5%. From these results, there
was no relationship between the length in years from the participants diagnosis and their relative
grip strength. Table 5 shows us the mean of relative grip strength z-scores for each cancer group.
Skin cancer, reproductive cancers, digestive, nervous, respiratory, musculoskeletal, renal and
endocrine cancers, and those with other or multiple cancers all had a mean score between 0.410.55; the z-scores being close to zero (the median) indicate that they are almost identical to the
larger sample the z-scores were derived from. None of the four groups statistically different.
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CHAPTER IV: DISCUSSION
The goal of this descriptive study was to investigate handgrip strength in cancer survivors
using the National Health and Nutrition Examination Survey (NHANES), a nationally
representative sample. This study aimed to look at relative hand grip strength z-scores in
individuals diagnosed with various types of cancer over many years, alongside covariates such as
age, sex, minority status, social economic status, BMI, and physical activity.
Prior studies have shown that many individuals diagnosed with cancer suffer from a loss
of muscle mass9 10 11. This negatively affects patients’ quality of life and cancer survival4 12
135/20/2021

4:16:00 PM. Previous research has also shown that increased strength and exercise

can have a positive impact for those diagnosed with cancer5 6. However, we found little evidence
that different cancer types were associated with relative grip strength. When examining the odds
ratio between skin cancers and all other types of cancer, all groups ranged between 1 to 2 times
more likely to have low grip strength, and none were found to be statistically different (p=0.074).
Individuals who were diagnosed within 3 years or less were 1.75 times more likely to score
lower for strength, but this was not statistically significant either. The association between
muscular strength and the number of years since each patient’s first diagnosis also was not found
to have any statistical significance in this study (p=0.068). Therefore, the cancer variables we
examined, cancer type or years since diagnosis, did not have an association with relative grip
strength.
From the literature, those who have higher strength are more likely to survive cancer7.
While the results of this study did not replicate those findings directly, we did find that those
who have higher PA (p=0.021) and lower BMI (p<0.001) are more likely to have higher relative
strength. Cancer survivors whose lifestyles lack activity, reporting no moderate to vigorous PA,
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were over 2 times more likely to have low relative grip strength. Likewise, a cancer survivor
classified as obese had an increased odds of low relative grip strength by almost 50 times over
normal weight survivors. The significant relationships between PA and BMI with strength,
highlights the importance of PA and BMI on survival.
In addition to PA and BMI, there were other findings from this study consistent with
previous research. The family monthly poverty level index from NHANES, which is calculated
by dividing family income by the poverty guidelines specific to family size, year, and state,
range from 1 to 5. The population in this study averaged a ratio of 3.6 for males, and 3.0 for
females, showing that many of these cancer survivors are well above the poverty level. Previous
research shows that in comparison to individuals with higher annual incomes, those with lower
incomes have been found to have shorter survival times and lower survival rates 14 15. For this
study’s cancer survivors, the average number of years since their most recent diagnosis was
about 10 years. These findings are coherent with research that shows higher income is related to
greater survival length and rates. Similarly in our findings, we categorized SES into two groups,
low SES and high SES, with a score of 2.28 as the cutoff. The low SES group had a mean of
0.44, and the high SES group has a mean of 0.56, for relative grip strength z-scores, with the
differences being statistically significant. This indicates that individuals with a higher SES will
also tend to score higher in grip strength, whereas those with low SES will score lower in grip
strength.
Previous research has also found that cancer patients who exercise have a lower relative
risk of cancer mortality and recurrence5. We explored grip strength z-scores by the number of
years since the patients’ diagnosis. However, years since diagnosis were not predictive of low
strength: those scoring in the lower 33rd percentile, or sufficient strength: those at or above the
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33rd percentile. In this sample, the largest proportion of survivors were 6 or more years away
from their diagnosis. Knowing that many cancers are most likely to reoccur within the first 2
years, and after 5 years likelihood of recurrence is even less, it is likely that our population is
relatively healthy considering more than half the population was already 6 or more years from
their diagnoses16. This also would give the subjects years to regain their strength and resume
their daily activities, which gives insight into the relative grip strength z-scores being analytically
insignificant. After the 6 or more years category, 1 year from diagnosis was the next highest
category for the low strength group. If the subjects’ cancer is currently being treated, previous
research shows this would impact their strength9. However, the other years are inconsistent, and
the population with sufficient strength is evenly spread throughout the years, thus we are not able
to conclude these findings as statistically significant.
The relative grip strength z-scores allows us to compare each individual’s strength scores
with others of the same demographic. Skin cancer averaged closest to 0 with a mean of 0.55;
reproductive, digestive, nervous, respiratory, musculoskeletal, renal and endocrine cancers had a
slightly lower mean of 0.49; those with other or multiple cancers had the lowest mean score of
0.41. All of these z-scores are near the median of the full NHANES dataset the z-scores were
derived from. In addition to this, none of the four groups were statistically different. This
demonstrates that our cancer survivor population is very similar in strength to our larger healthy
population and cancer type was not a significant predictor of strength.
Prior research indicates that for every 100,000 people, the number of individuals newly
diagnosed with cancer are 452 White, 440 Black, and 348 Hispanic; cancer death rates for every
100,000 cases are 156 White, 177 Black, and 110 Hispanic17. We can see from these previous
findings that the number of new diagnoses and the number of death rates do not have a large
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disparity between White and all other minority groups. However, the cancer survivors in our
sample were composed of 87% individuals who classified themselves as Non-Hispanic White,
and 13% classified as Mexican America, Non-Hispanic Black, Multiracial or other. This sample
shows a much larger disparity between those who identify as White and those who identify with
another race/ethnicity. Likewise, the mean relative grip strength z-scores for Non-Hispanic
White compared to the minority group were not found to be statistically significant.
This study had many strengths, including the use of a national representative dataset that
is generalizable to the noninstitutionalized US population. The data collection procedures were
carried out by certified technicians with standardized quality control procedures. However, this
study also had limitations, including over 30 cancer types, splitting the sample into many small
groups. NHANES data collection is also cross-sectional and was limited in their information on
cancer specifics (no inclusion of treatment, stage, current status, etc.).
In conclusion, this study was designed to look at relative grip strength z-scores in patients
diagnosed over many years with various types of cancer, including age, sex, minority status,
SES, BMI, and PA. Those who participated in more PA, had a lower BMI, and had higher SES,
were more likely to have higher grip strength z-scores. However, we did not find evidence for
cancer types or years since diagnosis to be predictive of low grip strength. It is likely that this
cancer survivor population is similar in health to the larger NHANES population. Future
longitudinal research is needed to look at grip strength from the moment of diagnosis, during
treatment, and after survival, in order to analyze grip strength differences over time in
individuals with cancer. Further studies should also explore grip strength in individuals receiving
different cancer treatments, grip strength in cancer patients with cachexia compared to those
without, and grip strength in relation to cancer stage.
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CHAPTER V: EXTENDED LITERATURE REVIEW
Patients who have been diagnosed with cancer often experience an involuntary loss of
weight, particularly from a loss of muscle mass, defined as cachexia 10. Cancer cachexia affects
quality of life (QoL), responsiveness to cancer treatments, and cancer survival negatively4. While
the scientific understanding of cachexia in the recent years has made many improvements, cancer
cachexia persists as an unmet medical need and efforts have been unsuccessful in solidifying a
standard treatment guideline4.
Numerous studies over the recent 35 years have reported that 50-80% of cancer survivors
are affected by involuntary weight loss; the degree of weight loss is dependent on the tumor type,
size, and stage of the cancer9. Knowing this, Ryan et al.9 explored the effects of weight loss and
sarcopenia in response to chemotherapy, quality of life, and survival in patients with cancer.
Recent data suggest that weight loss even as small as 2.4% predicts survival. This is independent
of the site or stage of cancer and their performance score. The significance of weight loss on overall
survival (OS) has been recognized for years, but more recent use of gold standard methods of body
composition has contributed to an increased understanding of the importance specifically of
muscle abnormalities. The gold standard method of computer tomography (CT scans) has shown
that muscle abnormalities are highly prevalent ranging from 10% up to 90%. Low muscle mass,
also known as Sarcopenia, and low muscle attenuation are the two most prevalent examples of
muscle abnormalities. These are essential prognostic indicators of unfavorable outcomes in cancer
patients. Both low muscle mass and low muscle attenuation have been associated with significant
deterioration in a patients' performance status, an increased risk of postoperative complications,
poorer tolerance to chemotherapy, and poorer psychological well-being, overall quality of life, and
survival.
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In 2018, Versteeg KS et al.13 also conducted a study to investigate whether muscle mass
and strength were associated with OS, but specifically in patients with advanced cancer, aged 60
years or older. Before starting chemotherapy, CT scans were used to assess muscle mass and
radiodensity, and a hydraulic hand grip dynamometer was used to assess muscle strength. There
were 103 participants, with a mean age of 70 years, and were diagnosed with either colorectal,
prostate, or breast cancer. The researchers found that, in older patients with advanced cancer,
higher muscle strength at the start of chemotherapy is associated with significantly better OS
(hazard ratio 1.03; 95% confidence interval 1.00–1.05). These results suggest that muscle strength
could be helpful in estimating cancer survival and could have a large impact on treatment plans.
Further research is needed to evaluate more specifically how muscle strength can be used for
treatment decisions.
A few years earlier in 2016 Deisenroth A. et al.11 also looked at muscle strength and QoL,
but specifically in cancer patients who were children in the early phase of primary treatment. In
children, muscle strength is crucial for developing motor performance and has an impact on the
child’s activities of daily living. In this study, 40 children and adolescents with various types of
cancer volunteered. The mean age of the participants was 11.39 years ± 4.08 years. The researchers
tested strength performance in a total of 7 muscle groups; the assessments included shoulder
abduction, elbow flexor/extensor, hip flexors, knee flexor/extensor, and dorsi-/plantar flexors of
the ankle. The participants also completed KINDL questionnaires, which evaluated the patients
QoL. Compared with age and gender matched controls, individuals with childhood cancer showed
significantly lower strength values in all muscle groups (p<0.1). The muscles that were most
affected were the lower extremities, with a score of -57.1% ± 10.4% (median: -59.2%, minimum:
-75.4%, maximum: -41.4%) percentage deviation from their healthy peers. The children and their
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parents assessed the total QoL to be significantly below age and gender matched reference values
as well (P < .01). This study shows that muscle weakness and decreased QoL in children and
adolescents seem to persist already at the beginning of cancer treatments. This underlines the need
of interventions, like exercise programs, to counteract these negative effects starting as early as
possible during the treatment process.
As previously stated above, muscle dysfunction and sarcopenia have been associated with
greater side effects, poor performance status, and an increased mortality risk in cancer patients.
However, insufficient research has examined how performance is affected by specific cancer
therapies. In 2017, Klassen O et al.12 investigated muscle strength in breast cancer patients in
different adjuvant treatment settings. They also compared it with data from healthy individuals.
The participants were 255 breast cancer patients from two randomized controlled exercise trials,
staged 0–III, and aged 54.4 years ± 9.4 years. The subjects were categorized into four groups
according to their treatment status. In addition, another 26 healthy women, aged 53.3
years ± 9.8 years, were also tested. The researchers assessed muscle function bilaterally through
maximal voluntary isometric contractions (MVIC) and maximal isokinetic peak torque (MIPT) by
isokinetic dynamometry in shoulder rotators and knee flexors and extensors. They also evaluated
shoulder flexibility and muscular fatigue index (FI%). Lower muscle strength was measured
consistently in knee and shoulder strength in subjects after chemotherapy. Patients with cancer had
on average up to 12-16% in upper extremities and 25% lower strength in lower extremities in
MVIC and MIPT compared with healthy women. Patients with radical mastectomy had
significantly lower shoulder flexibility, and patients with chemotherapy treatments had
consistently higher FI%. Before and after treatments, breast cancer patients displayed impaired
joint dysfunctions and muscle strength. Similar conclusions as the last study were drawn upon in
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this study, as significant differences between patients and healthy individuals highlight the need
of exercise therapy as early as possible in order to prevent and counteract the loss of muscle
function after treatments, in this case neo/adjuvant chemotherapy and surgery.
Another study done in women diagnosed with breast cancer was done by Perez CS et al. 18
in 2018. The researchers looked specifically at electromyography of the upper limbs, handgrip
strength, and their relationships with dominance in women who have undergone surgery as a
treatment for breast cancer. The study evaluated 28 women by measuring strength in their
descending trapezius, biceps brachial, triceps brachial, extensor carpi ulnaris, radial extensor carpi
and superficial flexor of wrist and fingers using electromyography; they also assessed grip strength
using a dynamometer. On the side affected by surgery, the researchers found a significant decrease
in hand grip strength and electromyography. However, grip strength showed greater differences
when the surgery was performed on the patients’ non-dominant side. This shows the need to
consider the specifics of treatment, in this case the side affected by surgery and their side of
dominance.
While breast cancer is the most common type of cancer among females, prostate cancer is
one of the most common types among males according to the American Institute for Cancer
Research7. In 2015, Gonzalez BD et al. examined changes in muscle strength and physical
functioning in men receiving androgen deprivation therapy (ADT) for prostate cancer 19. The
researchers assessed lower body strength through the Chair Rise Test, upper body strength through
Handgrip Dynamometry, and measured physical functioning using the SF-12 Physical Functioning
self-reported scale. First baseline measures were recorded before ADT began, again after 6
months, and last after 12 months. Physical functioning remained stable in prostate cancer controls,
but upper body muscle strength declined in the patients receiving ADT. Lower body strength in
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ADT group was lower than the control group, but lower body strength remained stable. The
researchers conclude that this information should be included in the education of risk and benefits
associated with ADT, and that further research needs to be done to find ways to prevent or reverse
declines in this patient population.
A less common cancer known as Hodgkin lymphoma impacted an estimated 215,531
people in the United States in 2017. In the same year, researcher de Lima FD et al.20 wanted to
assess fatigue, body composition, strength, muscle quality, and muscle thickness in Hodgkin’s
lymphoma survivors (HLS). The purpose of this was to compare them to apparently healthy
subjects that were matched by gender, age, and physical activity levels. They assessed fatigue
using the 20-item Multidimensional Fatigue Inventory. Body composition was assessed with dualenergy x-ray absorptiometry. They measured muscle strength an isokinetic dynamometer. Muscle
quality and thickness was measured through B-mode ultrasound. In this study, they discovered
that fatigue was significantly higher in HLS than in the healthy control group. Outside of this, there
were no significant differences observed. The researchers concluded that potential fatigue should
be considered when prescribing exercise training to this specific cancer population.
Another specific cancer type is esophageal. In 2016, Inoue T et al.21 sought to evaluate the
impact of radial esophagectomy on functional exercise capacity, muscle strength, anxiety,
depression, and health related QoL. This was done through a retrospective review of 34 patients
with newly diagnosed esophageal cancer, who underwent esophagectomy, and completed
postoperative rehabilitation. Hand grip strength, a 6-minute walk test, knee extensor muscle
strength, Chronic Obstructive Pulmonary Disease assessment test, and Hospital Anxiety and
Depressional Scale were all used to assess the cancer patients. These assessments were completed
before the surgery and two weeks post-surgery. All physical status was significantly poorer in
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patients with COPD than those without. There were significant decreases in hand grip strength,
the walk test, and knee extensor muscle strength between preoperative and postoperative. The
researchers concluded that these results indicate that surgery can be detrimental to patients’ health
outcomes at two weeks. They also suggest further research should investigate whether
prehabilitation would improve postoperative outcomes, QoL, and/or physical fitness.
Cancer cachexia, as stated earlier, has become understood greater in recent years, however
it still remains an unmet medical need, and standards for exercise have yet to be decided upon.
With the goal to try and help inform the design and duration of physical activity interventions
applicable to cancer patients with cachexia, Gale N et al. 10 teamed up in 2019 to research the
change in muscle strength and function over 8 weeks in patients with already established cancer
cachexia. They assessed isometric quadriceps and hamstring strength, handgrip strength, standing
balance, 10-m walk time, and timed up and go. The patients completed these assessments at
baseline, 4 weeks, and 8 weeks. Over the course of the 8 weeks there was little change in
performance. The authors consider their study to be exploratory in nature, with challenges such as
a small sample size and resultant limitations in interpreting the data. A longer longitudinal study
and a larger sample size may aid in more beneficial findings.
Similarly to guidelines concerning cachexia, there are no clear guidelines concerning
which type of exercise and which training dose are most effective in cancer patients specifically
receiving chemotherapy. In 2016, Van Moll CC et al.22 conducted a review to gain insight into the
different training modalities during chemotherapy and the effects of training to improve endurance
capacity and muscle strength. The researchers wanted to obtain the knowledge to compose a future
training program that most effectively trains cancer patients. They began with 809 randomized
controlled trials but only 14 met the inclusion criteria. Of these, the authors concluded that the
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studies were poor because the populations varied considerably, and the training programs were
very heterogeneous. All in all, more research is needed to find which intensity and duration is most
effective for cancer patients. Once this is more developed, hopefully international guidelines can
be implemented and put into daily practice.
The next article also looks at cancer relative to exercise. Dankel SJ et al.6 knew that skeletal
muscle strength and engagement in muscle strengthening activities are each inversely associated
with all-cause mortality, but they wanted to know more about their relationship with cancerspecific mortality. In 2018, the researchers used the National Health and Nutrition Examination
Survey to assess 2773 individuals aged 50 or older. After adjusting for covariates, individuals in
the upper quartile for muscle strength were at a 50% reduced risk of cancer specific mortality
(hazard ratio = 0.50; 95% confidence interval, 0.29-0.85; P = .01) and those meeting muscle
strengthening activities were at an 8% reduced risk of cancer specific mortality, however, this is
not statistically significant (hazard ratio = 0.92; 95% confidence interval, 0.45-1.86, P = .81). They
concluded that lower extremity strength should be routinely assessed and engagement in musclestrengthening activities aimed at increasing muscle strength should be promoted.
Another study that looks at the impact of exercise on cancer mortality was conducted in
2017 by Cormie P. et al.5; however, this study also aims to look at the impact on cancer recurrence
and treatment-related adverse effects. This systematic review comprehensively summarized the
available randomized control trial and epidemiologic evidence that investigated the role of exercise
in the management of cancer. The authors gathered 100 studies involving thousands of patients
whose exercise behavior was assessed following the diagnosis of any type of cancer. In comparison
with patients who performed no or less exercise, patients who exercised, following a diagnosis of
cancer, were observed to experience fewer or less adverse effects and have a lower relative risk of
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cancer mortality and recurrence. These findings support the stance that exercise should be
supplemented in cancer management.
One final systematic review that examines physical activity in cancer prevention and
survival was comprised of 45 reports and was published in 2019, authored by McTiernan A. et
al.7. The article found strong evidence for an association between reduced risk of bladder, breast,
colon, endometrial, esophageal, renal, and gastric cancers and highest versus lowest physical
activity levels. Relative risk reductions ranged from approximately 10-20%. They also found
moderate associations between decreased all cause and cancer specific mortality and greater
amounts of physical activity in individuals with a diagnosis of breast, colorectal, or prostate cancer,
with up to a 40-50% risk reduction. Levels of physical activity recommended in the 2018 Physical
Activity Guidelines Advisory Committee Scientific Report are associated with improved survival
and risk reduction for several cancers. Further research should explore dose-response relationships
and aim to establish mechanisms to explain these associations.
Summary
Cancer cachexia, loss of muscle mass, negatively affects responsiveness to cancer
treatments, quality of life (QoL), and cancer survival. Many patients experience weight loss,
which was found to be largely in part of sarcopenia, low muscle mass, and low muscle
attenuation. These muscle abnormalities have been associated with significant deterioration in a
patients' performance status, an increased risk of postoperative complications, poorer tolerance to
chemotherapy, and poorer psychological well-being, overall quality of life, and survival. The
literature suggests this is true for older patients aged 60 years or older, children from the very
beginning of their treatments, individuals diagnosed with Hodgkin lymphoma, breast, prostate,
esophageal, bladder, colon, endometrial, renal, and gastric cancers. There are currently no
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guidelines concerning cachexia or which type of exercise (type and dose) are most effective.
However, this research does show that muscular strength is an important factor in survival and
reduces adverse effects. After reviewing the above studies, it is clear muscle strengthening
activities should be incorporated into the treatments of cancer patients.
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